. Author manuscript; available in PMC: 2011 Jul 22.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 May 1;57(1):32–39. doi: 10.1097/QAI.0b013e3182119244

Table 2.

Unadjusted and adjusted hazards ratios for progression-free survival (PFS) by HLA alleles.

Alleles	Comparisons	Unadjusted HR (95%CI)	p-value	Adjusted^a HR (95%CI)	p-value	Adjusted^b HR (95%CI)	p-value
A	homozygotes vs. heterozygotes	0.82 (0.44,1.51)	0.52	2.23 (0.77,6.48)	0.14	0.86 (0.46,1.62)	0.64
B	homozygotes vs. heterozygotes	1.66 (1.01,2.74)	0.05	1.63 (0.62,4.34)	0.32	1.55 (0.90,2.66)	0.11
C	homozygotes vs. heterozygotes	1.55 (1.00,2.42)	0.05	0.80 (0.35,1.84)	0.6	1.63 (1.02,2.60)	0.04
DRB1	homozygotes vs. heterozygotes	1.48 (0.95,2.29)	0.08	1.60 (0.77,3.30)	0.2	1.46 (0.92,2.31)	0.11
B-27	presence vs. absence	-	^*<0.0001	-	-	-	-
B-57	presence vs. absence	0.54 (0.26,1.14)	0.11	0.74 (0.15,3.73)	0.72	0.51 (0.23,1.14)	0.1
Cw-2	presence vs. absence	0.48 (0.28,0.81)	0.006	1.16 (0.48,2.78)	0.75	0.46 (0.27,0.79)	<0.0001
Cw-6	presence vs. absence	1.43 (0.99,2.07)	0.06	1.43 (0.59,3.49)	0.43	1.41 (0.96,2.06)	0.08
DQB1-2	presence vs. absence	0.66 (0.47,0.92)	0.01	0.57 (0.32,1.03)	0.06	0.67 (0.48,0.94)	0.02

Adjusted for baseline covariates: race, gender, age, baseline log HIV-1 RNA, change of log HIV-1 RNA from baseline to week 24 and 48, baseline CD4⁺ lymphocyte count and percent, change of CD4⁺ lymphocyte count from baseline to week 24 and 48, Baseline WAZ Score and treatment.

Adjusted for other genotypes: CCR5-wt/Δ32, CX₃CR1-249-V/I, -280-T/M, SDF-1-180-G/A, and MBL2-A/O.

The p-value is from the robust score test of the Cox model in order to account for the sampling weight in the variance estimation. Since none of the subjects possessing the B-27 allele was observed to have a HIV-1-related disease progression endpoint during follow-up, no HR and 95% CI estimates can be calculated.